Home > Boards > US Listed > Biotechs > Seattle Genetics (SGEN)

Our main product is not free of possible

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
shub Member Profile
 
Followed By 12
Posts 1,387
Boards Moderated 0
Alias Born 04/12/11
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/20/2020 5:34:37 PM
Five Prime Therapeutics In License Agreement with Seattle Genetics Dow Jones News - 2/19/2020 10:31:00 AM
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combina... PR Newswire (US) - 2/19/2020 8:28:00 AM
Seattle Genetics & Astellas Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combinati... Business Wire - 2/19/2020 8:12:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 1:38:19 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 12:11:05 PM
Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients wit... Business Wire - 2/13/2020 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/12/2020 5:39:52 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 2:53:27 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 11:15:05 AM
Seattle Genetics & Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combinat... Business Wire - 2/11/2020 8:00:00 AM
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combin... PR Newswire (US) - 2/10/2020 5:00:00 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/7/2020 8:46:46 AM
Annual Report (10-k) Edgar (US Regulatory) - 2/6/2020 5:19:34 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/6/2020 4:11:25 PM
Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire - 2/6/2020 4:02:00 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 2/6/2020 12:54:01 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/5/2020 6:08:55 PM
EMA Validates Seattle Genetics’ Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Met... Business Wire - 1/31/2020 8:00:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 1/28/2020 9:11:39 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 1/28/2020 9:10:31 AM
Schedule 13g Edgar (US Regulatory) - 1/27/2020 3:57:34 PM
Seattle Genetics to Host Conference Call & Webcast Discussion of Fourth Quarter & Full Year 2019 Financial Results on Februar... Business Wire - 1/21/2020 8:30:00 AM
Seattle Genetics Achieves Milestone Following European Commission Approval of Roche’s Polivy® (Polatuzumab Vedotin) Business Wire - 1/21/2020 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/16/2020 4:56:53 PM
shub   Thursday, 01/26/17 03:03:32 PM
Re: north40000 post# 218
Post # of 254 
Our main product is not free of possible nasty side effects...It's the nature of the beast. We poison both you and your cancer and try to trim it so you survive and the cancer doesn't. It tends to be a fine line. The alternative tends to be death.
Clinical holds come with the territory.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist